TickerTalks
Browse all tickers →
TickerTalks›$CVRX
CVCVRX

CVRx, Inc.

$CVRX·$63M·Medical - Devices·Healthcare
$2.96+0.3%YTD-23.2%1Y-62.6%
Mentions · last 7 days
2026-08-21: 0 posts2026-08-22: 0 posts2026-08-23: 1 posts10-25%
Price updated 14m ago·X counts updated 8d ago
CVCVRX
$CVRXCVRx, Inc.
$2.96+0.34%10 posts-25%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CVRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-30

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

CVRx $60M nano-cap — Pointillist activist 5.5% stake with call-to-sell letter, Barostim Devoted Health coverage Aug 28, Pomerantz.

CVRx Inc. is a $60M medical-device nano-cap (Barostim for heart failure). Fresh activist Pointillist Family Office 5.5% stake with call-to-sell letter plus Pomerantz investigation.

How it reads:

  • Growth is real: Q1 revenue +19.6% YoY to $15M, Q4 was +15.1% — sustained mid-teens compounding at small scale.
  • Margins are catastrophic: -85% operating margin (Q1), -28% FCF yield, -55% ROIC — heavy commercial burn.
  • Valuation is compressed: -2.69x PE (near-zero base), 2.4x sales, -2.66x EV/EBITDA — priced on activist outcome, not P&L.
  • Position is at 52w low: 8.2th percentile 52w, 34.5% below 50-day, 55.8% below 200-day on 42% baseline volume — the tape is broken.
  • Aug 24 Pointillist Family Office 5.5% stake + call-to-sell letter after 59% single-day crash — activist catalyst.
  • 'Activist low-hanging fruit': unique asset, net cash, sub-1x revenues, 4-6x mcap invested to get product approved.
  • Aug 28 Devoted Health coverage for Barostim — commercial-defense tell.
  • Aug 27 Pomerantz + Hagens Berman investigations — class-action overhang.
  • Aug 11 CRO Robert John terminated — governance turmoil.
  • Insider small bullish: $76K P-Purchase (Binkowski director) — small officer buy in -34% tape.

The Nov 4 print is the test — a specific Barostim-reimbursement momentum plus reiterated activist plan defends the setup; another guidance miss plus Pomerantz-driven complaint filing drops to $2 support.

Agrees with X sentimentAgree — the bullish anchors (Pointillist Family Office / Jorey Chernett took 5.5% and sent call-to-sell-the-company letter following 59% single-day crash three weeks prior, CVRX as classic activist low-hanging fruit with unique asset, net cash, sub-1x revenues in attractive interventional category, 4-6x current market cap invested to get product approved) map to real signals; the honest add is Aug 27 Pomerantz + Hagens Berman investigations plus Aug 11 CRO termination are the load-bearing risks to name.

What to watch: Nov 4 earnings — a specific Barostim-reimbursement momentum plus reiterated activist plan defends the setup; another guidance miss plus Pomerantz-driven complaint filing drops to $2 support.

On the calendar: 2026-11-04 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-30

The CVRx thread is bullish and activist-driven following a letter from Pointillist Family Office, which holds 5.5%, calling on the company to sell. Posters describe it as classic activist low-hanging fruit with a unique asset, net cash, and trading sub-1x revenue in an attractive category. One post estimates the company has invested 4-6x current market cap in getting the product approved and reimbursed, making a 2-3x strategic bid plausible.

Read the AI verdict + X sentiment for $CVRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes Barostim, an implantable device stimulating cardiac baroreceptors to treat heart failure through neural modulation.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $CVRX.

Medical - Devices · Healthcare

Elective procedure volume recovery and aging-demographic demand are the structural drivers; robotic surgery adoption (ISRG) and GLP-1-driven procedure mix shifts are the near-term dynamics. Hospital capex cycles determine device upgrade timing — CapEx returning after COVID deferral.

What this means for $CVRX

Partial — medical device revenue depends on elective procedure volumes and hospital capex; CVRx, Inc.

Industry benchmark

25-name peer basket
+9.0%YTD
+29.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-55.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-84.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-121%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
85.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.53$-0.52-1.0%
Q1 2026May 11, 2026$-0.50$-0.51+2.0%
Q4 2025Feb 12, 2026$-0.46$-0.42-9.5%
Q3 2025Nov 5, 2025$-0.49$-0.50+2.0%
Next earningsWed, Nov 4·consensus EPS $-0.49

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$14.8M+19.6%87.2%-82.3%$-0.50$-12.3M
Q4 FY25$16.0M+4.4%86.3%-69.8%$-0.46$-9.8M
Q3 FY25$14.7M+9.8%85.5%-83.5%$-0.49$-10.0M
Q2 FY25$13.6M+15.1%82.8%-106%$-0.57$-8.0M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$65.3M$65.1M – $65.7M-$1.96-$2.11 – -$1.815
FY27$76.1M$75.3M – $77.4M-$1.90-$2.27 – -$1.495
FY28$95.6M$85.8M – $104.5M-$1.67-$2.21 – -$1.054
FY29$120.6M$116.2M – $125.7M-$1.37-$1.45 – -$1.313
FY30$133.8M$129.0M – $139.4M-$1.21-$1.28 – -$1.153

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.8%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-34.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-55.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 18.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.825-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 13Brent BinkowskiCOO26.2K sh$76KSellAug 12Brent BinkowskiCOO1.3K sh$3K
+ 7 other (7 awards) in window

See when $CVRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13DActivist position (5%+)Aug 24SC 13D
AI summary

Jorey Chernett (6222 Indianwood Tr., Suite 650, Bloomfield Hills MI) filed an initial Schedule 13D on CVRx, Inc. (CVRX) Common Stock ($0.01 par value) on August 24, 2026, disclosing a new 5%+ beneficial ownership position. An initial SC 13D (rather than 13G) signals non-passive investment intent — Chernett is a new activist or strategic investor in CVRx. CVRx develops baroreflex activation therapy (BAT) devices for treatment-resistant hypertension and heart failure. This is a notable new activist or significant ownership entry in a small medical device company.

8-KOfficer or director changeAug 118-K — Item 5.02: Officer or director change
AI summary

CVRx (CVRX) disclosed that Robert John, its Chief Revenue Officer, was terminated effective immediately on August 10, 2026 under circumstances entitling him to severance pay and benefits under his employment agreement. No reason for the termination was provided beyond that the departure qualifies for severance. The company did not announce a permanent or interim replacement in this filing.

8-KOfficer or director changeJun 98-K — Item 5.02: Officer or director change
AI summary

CVRx, Inc. CFO Jared Oasheim notified the company on June 7, 2026 of his intent to resign to pursue other professional opportunities; an Employment Transition Agreement signed June 8, 2026 provides that he will stay as full-time CFO at current salary until the later of August 31, 2026 or 30 days after his successor starts, then serve as a consultant through February 2027 at $245/hour. CVRx will pay a $262,000 cash transition payment in two equal installments (November 30, 2026 and February 28, 2027), preserve his full 2026 incentive eligibility, extend pre-2021 stock option exercise windows to three months after the consulting period ends, and reimburse up to $10,000 in legal fees. A CFO search is underway, representing a near-term leadership transition risk at this commercial-stage medical device company.

3New insider — initial holdingsJun 33
AI summary

Dale Michael D filed a Form 3 with the SEC, disclosing initial beneficial ownership of CVRX securities. This filing is required under Section 16(a) of the Securities Exchange Act within 10 days of becoming a reporting person (officer, director, or 10%+ holder). The filing reports 4 shares of common stock. Form 3 filings establish a baseline ownership record for subsequent Form 4 (changes) and Form 5 (annual) filings, providing transparency into insider positions at CVRX.

8-KShareholder voteJun 38-K — Item 5.07: Shareholder vote
AI summary

CVRx, Inc. (CVRX) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on ratification of the independent auditor. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

3New insider — initial holdingsMar 43
+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CVRx Secures Devoted Health Coverage for Barostim Therapyzacks.com·3d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claimsprnewswire.com·4d agoHAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Dropprnewswire.com·5d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRXglobenewswire.com·6d agoCVRx Responds to Letter from Pointillist Family Officeglobenewswire.com·7d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MDT$TMDX$BIO$ABT$BFLY$BSX$SYK$CLPT
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport